Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06933056
EARLY_PHASE1

Comparison of Antiplatelet Effects of Sotagliflozin to FDA-approved Antiplatelet Drugs

Sponsor: University of Michigan

View on ClinicalTrials.gov

Summary

This study will identify the potential benefits of regulating platelet activation with sotagliflozin compared to other FDA-approved drugs known to limit platelet activation.

Official title: Comparison of Antiplatelet Effects of Sotagliflozin to FDA-approved Antiplatelet Drugs: an Interventional Study

Key Details

Gender

All

Age Range

18 Years - 79 Years

Study Type

INTERVENTIONAL

Enrollment

20

Start Date

2025-09-02

Completion Date

2026-09

Last Updated

2025-09-15

Healthy Volunteers

Yes

Interventions

DRUG

Sotagliflozin (SOTA) followed by 3 drugs in a random order

400 mg/day SOTA Each drug will be given daily for 2 weeks.

DRUG

Aspirin followed by 3 drugs in a random order

81 mg/day Aspirin Each drug will be given daily for 2 weeks.

DRUG

Clopidogrel followed by 3 drugs in a random order

75 mg/day clopidogrel Each drug will be given daily for 2 weeks.

DRUG

Eliquis followed by 3 drugs in a random order

5 mg orally twice daily Eliquis Each drug will be given daily for 2 weeks.

Locations (1)

University of Michigan

Ann Arbor, Michigan, United States